Vertex Pharmaceuticals Incorporated (OQ:VRTX)

Sector:  Healthcare Industry:  Biotechnology & Medical Research
 
See Regulatory Filings on SEC
Company Contact
Address: 50 Northern Ave
BOSTON MA 02210-1862
Tel: 1-617-9616108
Website: https://www.vrtx.com
IR: See website
<
Key People
Jeffrey M. Leiden
Chairman of the Board, President, Chief Executive Officer
Paul M. Silva
Senior Vice President, Controller
Charles F. Wagner
Chief Financial Officer, Executive Vice President
Michael J. Parini
Executive Vice President, Chief Legal and Administrative Officer
David Altshuler
Executive Vice President - Global Research, Chief Scientific Officer
Stuart A. Arbuckle
Executive Vice President, Chief Commercial Officer
Carmen Bozic
Executive Vice President - Global Medicines Development and Medical Affairs, Chief Medical Officer
Gerald W. Bruce
Executive Vice President, Commercial Operations
Reshma Kewalramani
Executive Vice President - Global Medicines Development and Medical Affairs, Chief Medical Officer
Amit K. Sachdev
Executive Vice President, Chief Regulatory Officer and Chief of Staff to the CEO
   
Business Overview
Vertex Pharmaceuticals Incorporated is engaged in discovering, developing, manufacturing and commercializing medicines for serious diseases. The Company is focused on developing and commercializing therapies for the treatment of cystic fibrosis (CF) and advancing its research and development programs in other indications. The Company's marketed medicines are ORKAMBI and KALYDECO. ORKAMBI (lumacaftor in combination with ivacaftor) is approved as a treatment for patients having two copies (homozygous) of the Delta-F508 (F508del) mutation in their cystic fibrosis transmembrane conductance regulator (CFTR) gene. KALYDECO (ivacaftor) is approved for the treatment of CF patients having the G551D mutation or other specified mutations in their CFTR gene. The Company's development programs in the field of CF include Tezacaftor (VX-661), VX-152, VX-440, VX-659, VX-445 and VX-371. VX-152, VX-440, VX-659 and VX-445 are CFTR corrector compounds.
Financial Overview
For the fiscal year ended 31 December 2019, Vertex Pharmaceuticals Incorporated revenues increased 37% to $4.16B. Net income applicable to common stockholders excluding extraordinary items increased from $536.4M to $1.18B. Revenues reflect United States segment increase of 29% to $3.06B, Europe` segment increase of 63% to $885.8M. Net income benefited from Other expense, net - Balancing value increase from $1.4M (expense) to $187.3M (income).
Employees: 3,000 as of Dec 31, 2019
Reporting Currency: U.S. Dollars
Enterprise value: $58,210M as of Dec 31, 2019
Annual revenue (TTM): $4,163M as of Dec 31, 2019
EBITDA (TTM): $1,309M as of Dec 31, 2019
Net annual income (TTM): $1,177M as of Dec 31, 2019
Free cash flow (TTM): $1,494M as of Dec 31, 2019
Net Debt Last Fiscal Year: N/A
Shares outstanding: 259,268,593 as of Jan 31, 2020
Index Membership: S&P 500
TTM: Trailing Twelve Months
EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization